泌尿系统子宫内膜异位症:初次手术切除后如何预测和预防复发
这项回顾性单中心研究纳入2016年1月至2020年3月间在意大利一家子宫内膜异位症多学科转诊中心接受手术切除的105例泌尿系统子宫内膜异位症(UTE)患者,分析临床和手术预测因素。中位随访39个月,30例(28.6%)疾病复发,其中14例(13.3%)为泌尿系统复发。多因素分析显示,首次手术年龄<25岁(OR 1.23,95%CI 1.10-1.84,p=.02)和合并自身免疫病(OR 1.45,95%CI 1.24-2.17,p=.02)是深部浸润型子宫内膜异位症复发的预测因素,术后辅助激素治疗有保护作用(OR 0.83,95%CI 0.53-0.98,p=.01)。
要点
- 105例UTE患者术后中位随访39个月,疾病复发30例(28.6%),泌尿系统复发14例(13.3%)。
- 首次手术年龄<25岁(OR 1.23,95%CI 1.10-1.84,p=.02)是复发的预测因素。
- 合并自身免疫病(OR 1.45,95%CI 1.24-2.17,p=.02)是复发的预测因素。
核心结论
- 年轻(<25岁)和合并自身免疫病是疾病复发的显著预测因素,术后辅助激素治疗有保护作用。
研究设计与样本
- 回顾性单中心研究,纳入连续接受手术治疗的UTE患者105例,手术时间为2016年1月至2020年3月。
主要发现
- 中位年龄32岁(四分位距24-37),输尿管受累53例(50.5%),其中单侧46例(43.8%)、双侧7例(6.7%),膀胱受累52例(49.5%)。
- 开放手术24例(22.9%),腹腔镜手术30例(28.5%),机器人辅助手术51例(48.6%)。
- 53例(50.5%)接受辅助激素治疗;中位随访39个月(四分位距22-51),疾病复发30例(28.6%),其中泌尿系统复发14例(13.3%)。
- 多因素分析显示,首次手术年龄<25岁(OR 1.23,95%CI 1.10-1.84,p=.02)和合并自身免疫病(OR 1.45,95%CI 1.24-2.17,p=.02)是深部浸润型子宫内膜异位症复发的预测因素。
- 术后辅助激素治疗有保护作用(OR 0.83,95%CI 0.53-0.98,p=.01)。
关键数值与推荐
- 首次手术年龄<25岁:OR 1.23(95%CI 1.10-1.84,p=.02),预测深部浸润型子宫内膜异位症复发。
- 合并自身免疫病:OR 1.45(95%CI 1.24-2.17,p=.02),预测深部浸润型子宫内膜异位症复发。
- 术后辅助激素治疗:OR 0.83(95%CI 0.53-0.98,p=.01),有保护作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To investigate the clinical and surgical predictors of urinary tract endometriosis (UTE) relapse. DESIGN: Retrospective single institutional study. SETTING: Italian multidisciplinary referral center for endometriosis. PATIENTS: Consecutive patients affected by UTE and surgically treated between January 2016 and March 2020. INTERVENTION: Surgical excision for UTE. Uni- and multivariate logistic regression analyses were fitted to evaluate clinical and surgical predictors of recurrence. MEASUREMENTS AND MAIN RESULTS: A total of 105 female age-reproductive patients were enrolled. Median age was 32 years (interquartile range, 24-37). Ureteral involvement was recorded in 53 patients (50.5%), being unilateral and bilateral in 46 patients (43.8%) and 7 patients (6.7%), respectively. Bladder involvement occurred in 52 patients (49.5%). Open surgical approach was performed in 24 cases (22.9%), whereas 30 patients (28.5%) and 51 patients (48.6%) were treated with laparoscopic and robot-assisted approach, respectively. Overall, 53 patients (50.5%) received adjuvant hormonal therapy. At a median follow-up of 39 months (interquartile range, 22-51), 30 patients (28.6%) experienced disease relapse, with 14 recurrences (13.3%) recorded at the level of the urinary tract. At multivariable analysis, age at first surgery <25 years (odds ratio [OR], 1.23; 95% confidence interval [CI], 1.10-1.84; p = .02) and the presence of a concomitant autoimmune disease (OR, 1.45; 95% CI, 1.24-2.17; p = .02) were found as predictors of deep infiltrating endometriosis recurrence, whereas adjuvant postsurgical therapy showed a protective role (OR, 0.83; 95% CI, 0.53-0.98; p = .01). CONCLUSIONS: Young age (<25 years) and the presence of autoimmune diseases were significant predictors for the development of disease recurrence, whereas adjuvant hormonal therapy showed a protective role.
引用
- Di Maida F, Lambertini L, Grosso AA, et al. Urinary Tract Endometriosis: How to Predict and Prevent Recurrence after Primary Surgical Excision. J Minim Invasive Gynecol. 2022. PMID: 35817366. doi:10.1016/j.jmig.2022.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。